JAK mutations, particularly those affecting JAK1 and JAK2, are oncogenic in both acute lymphoblastic leukemia (ALL) (46,47) and myeloproliferative neoplasms (MPN). The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.